Oncolys BioPharma (TSE:4588) Long-Term Debt: 円66.66 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4588 Oncolys BioPharma Inc TSE:4588
37 GF Score
Price 円2,463.00
GF Value 円359.54
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Oncolys BioPharma Long-Term Debt?

Oncolys BioPharma TSE:4588 +0.49% 37 Long-Term Debt is 円66.66 Mil as of Dec. 2025. GuruFocus rates TSE:4588 with a GF Score™ of 37/100 and a GF Value™ of 円359.54 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Oncolys BioPharma's Long-Term Debt for the quarter that ended in Dec. 2025 was 円66.66 Mil.

Oncolys BioPharma's quarterly Long-Term Debt increased from Mar. 2025 (円144.43 Mil) to Jun. 2025 (円194.44 Mil) but then declined from Jun. 2025 (円194.44 Mil) to Dec. 2025 (円66.66 Mil).

Oncolys BioPharma's annual Long-Term Debt increased from Dec. 2023 (円161.10 Mil) to Dec. 2024 (円166.66 Mil) but then declined from Dec. 2024 (円166.66 Mil) to Dec. 2025 (円66.66 Mil).

Oncolys BioPharma  (TSE:4588) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Oncolys BioPharma Long-Term Debt Related Terms

Oncolys BioPharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Oncolys BioPharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolys BioPharma Long-Term Debt Chart

Oncolys BioPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 255.54 155.54 161.10 166.66 66.66

Oncolys BioPharma Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 166.66 144.43 194.44 66.66 44.43
TSE:4588
37GF Score
Oncolys BioPharma Inc TSE:4588
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of 円66.66 Mil mean?
Oncolys BioPharma (TSE:4588) has a Long-Term Debt of 円66.66 Mil as of Dec. 2025.
Is Oncolys BioPharma's Long-Term Debt too high?
Oncolys BioPharma's current Long-Term Debt is 円66.66 Mil. Overall, Oncolys BioPharma has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's Long-Term Debt compare to VRTX and REGN?
Oncolys BioPharma's Long-Term Debt of 円66.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Oncolys BioPharma's current Long-Term Debt is 円66.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円359.54, compared to a current price of 円2,463.00 — trading 585% above its estimated fair value. The current Long-Term Debt is 円66.66 Mil. Oncolys BioPharma's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current Long-Term Debt is 円66.66 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?

Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued. The current stock price of 円2,463.00 is trading 585% above its estimated GF Value™ of 円359.54. GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.

Key valuation signals for TSE:4588:

  • Long-Term Debt: 円66.66 Mil
  • GF Value™: 円359.54 vs. price of 円2,463.00 (585% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncolys BioPharma Business Description

Address 4-1-28 Toranomon, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
37GF Score

Get the complete analysis for TSE:4588

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,463.00
Price
円359.54
GF Value